Should radioiodine now be first line treatment for Graves’ disease?

Should radioiodine now be first line treatment for Graves’ disease?

Abstract Background Radioiodine represents a cost-effective treatment option for Graves’ disease. In the UK, it is traditionally reserved for patients who relapse after initial thionamide therapy. In a change from current practice, the new guidelines of the National Institute for Health and Care Exc...

Full description

Bibliographic Details
Main Authors: Onyebuchi E. Okosieme, Peter N. Taylor, Colin M. Dayan
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Thyroid Research
Subjects:
Graves’ disease
Hyperthyroidism
Radioiodine therapy
Thyroidectomy
Mortality
Major adverse cardiovascular events
Online Access:http://link.springer.com/article/10.1186/s13044-020-00077-8

Internet

http://link.springer.com/article/10.1186/s13044-020-00077-8

Similar Items